Chargement en cours...
IL-33 in Tumor Immunity: Nothing to Sneeze At
Although immunotherapy has been at the forefront of cancer therapy for the last several years, better clinical responses are still desired. Interleukin-33 is perhaps one of the most overlooked antitumor cytokines. Its ability to promote type 1 immune responses, winch control tumor growth in preclini...
Enregistré dans:
| Publié dans: | Crit Rev Immunol |
|---|---|
| Auteurs principaux: | , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
2018
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7087446/ https://ncbi.nlm.nih.gov/pubmed/31002600 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1615/CritRevImmunol.2018026335 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|